BridgeBio Pharma, Inc. Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2024-11-12: Disclosure Material Terms Of Trading Arrangement; Period 2024-07-01..2024-09-30; Value On August 30, 2024 , Frank McCormick , a member of our Board of Directors , adopted a trading plan on behalf of the Francis P. McCormick Revocable Trust U/A DTD 1/27/2017, of which Dr. McCormick is a trustee, for the sale of a maximum of 300,000 shares of our common stock (the “Trading Plan”). The T….
- 2024-05-02: Disclosure Material Terms Of Trading Arrangement; Period 2024-01-01..2024-03-31; Value On March 7, 2024 , Dr. Hannah A. Valantine , a member of our Board of Directors , terminated a trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) for the potential sale of a maximum of 34,980 shares of our common stock. Dr. Valantine’s tradi….
- 2024-04-25: Disclosure Pay versus Performance Table; Period 2023-01-01..2023-12-31; Value Pay-Versus-Performance The Compensation Committee approves and administers our executive compensation program, which it designs to attract, incentivize, reward, and retain our executive officers. Our program aligns executive pay with shareholder interests and links pay to performance through a blend….
- 2024-04-25: Disclosure Named Executive Officers Footnote; Period 2023-01-01..2023-12-31; Value (1) The dollar amounts reported in column (b) represent the amount of total compensation reported for Dr. Kumar (our “PEO”) for each corresponding covered year in the “Total” column of the Summary Compensation Table for each applicable year. Please refer to “Executive Compensation – 2023 Summary Com….
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2024-11-12 10-Q | Material Terms Of Trading Arrangement | 2024-07-01..2024-09-30 | On August 30, 2024 , Frank McCormick , a member of our Board of Directors , adopted a trading plan on behalf of the Francis P. McCormick Revocable Trust U/A DTD 1/27/2017, of which Dr. McCormick is a trustee, for the sale of a maximum of 300,000 shares of our common stock (the “Trading Plan”). The T… | |
| 2024-05-02 10-Q | Material Terms Of Trading Arrangement | 2024-01-01..2024-03-31 | On March 7, 2024 , Dr. Hannah A. Valantine , a member of our Board of Directors , terminated a trading plan intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c) for the potential sale of a maximum of 34,980 shares of our common stock. Dr. Valantine’s tradi… | |
| 2024-04-25 DEF 14A | Pay versus Performance Table | 2023-01-01..2023-12-31 | Pay-Versus-Performance The Compensation Committee approves and administers our executive compensation program, which it designs to attract, incentivize, reward, and retain our executive officers. Our program aligns executive pay with shareholder interests and links pay to performance through a blend… | |
| 2024-04-25 DEF 14A | Named Executive Officers Footnote | 2023-01-01..2023-12-31 | (1) The dollar amounts reported in column (b) represent the amount of total compensation reported for Dr. Kumar (our “PEO”) for each corresponding covered year in the “Total” column of the Summary Compensation Table for each applicable year. Please refer to “Executive Compensation – 2023 Summary Com… | |
| 2024-04-25 DEF 14A | Adjustment To PEO Compensation Footnote | 2023-01-01..2023-12-31 | (2) The dollar amounts reported in column (c) represent the amount of “compensation actually paid” to Dr. Kumar, as computed in accordance with Item 402(v) of Regulation S-K for each covered fiscal year. The dollar amounts do not reflect the actual amount of compensation earned or received by or pai… | |
| 2024-04-25 DEF 14A | Adjustment To Compensation | AdjToComp: ReportedGrantDateFairValueOfEquityAwardsInSummaryCompensationTable; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | -$10.62M |
| 2024-04-25 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardAdjustments; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $68.53M |
| 2024-04-25 DEF 14A | Adjustment To Compensation | AdjToComp: YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInCoveredFiscalYearAsOfEndOfCoveredFiscalYear; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $32.81M |
| 2024-04-25 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorFiscalYearsAsOfEndOfCoveredFiscalYear; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $17.61M |
| 2024-04-25 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInCoveredFiscalYear; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $4.43M |
| 2024-04-25 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorFiscalYearsThatVestedInCoveredFiscalYear; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $13.67M |
| 2024-04-25 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueAtEndOfPriorFiscalYearOfOutstandingAndUnvestedEquityAwardsGrantedInPriorFiscalYearsThatFailedToMeetVestingConditionsDuringCoveredFiscalYear; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $0.00 |
| 2024-04-25 DEF 14A | Adjustment To Compensation | AdjToComp: DollarValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsInCoveredFiscalYearPriorToVestingDateNotOtherwiseIncludedInTotalCompensationForCoveredFiscalYear; ExecutiveCategory: Peo | 2023-01-01..2023-12-31 | $0.00 |
| 2024-04-25 DEF 14A | Adjustment To Non PEO NEO Compensation Footnote | 2023-01-01..2023-12-31 | (4) The dollar amounts reported in column (e) represent the average amount of “executive compensation actually paid” to our CFO, as computed in accordance with Item 402(v) of Regulation S-K for each covered fiscal year. The dollar amounts do not reflect the actual average amount of compensation earn… | |
| 2024-04-25 DEF 14A | Adjustment To Compensation | AdjToComp: ReportedGrantDateFairValueOfEquityAwardsInSummaryCompensationTable; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | -$5.50M |
| 2024-04-25 DEF 14A | Adjustment To Compensation | AdjToComp: EquityAwardAdjustments; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $27.92M |
| 2024-04-25 DEF 14A | Adjustment To Compensation | AdjToComp: YearEndFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInCoveredFiscalYearAsOfEndOfCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $16.99M |
| 2024-04-25 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorFiscalYearsAsOfEndOfCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $4.94M |
| 2024-04-25 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueAsOfVestingDateOfEquityAwardsGrantedAndVestedInCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $2.30M |
| 2024-04-25 DEF 14A | Adjustment To Compensation | AdjToComp: YearOverYearChangeInFairValueOfOutstandingAndUnvestedEquityAwardsGrantedInPriorFiscalYearsThatVestedInCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $3.70M |
| 2024-04-25 DEF 14A | Adjustment To Compensation | AdjToComp: FairValueAtEndOfPriorFiscalYearOfOutstandingAndUnvestedEquityAwardsGrantedInPriorFiscalYearsThatFailedToMeetVestingConditionsDuringCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $0.00 |
| 2024-04-25 DEF 14A | Adjustment To Compensation | AdjToComp: DollarValueOfDividendsOrOtherEarningsPaidOnStockOrOptionAwardsInCoveredFiscalYearPriorToVestingDateNotOtherwiseIncludedInTotalCompensationForCoveredFiscalYear; ExecutiveCategory: NonPeoNeo | 2023-01-01..2023-12-31 | $0.00 |
| 2024-04-25 DEF 14A | Equity Valuation Assumption Difference Footnote | 2023-01-01..2023-12-31 | Equity Award Valuations : Stock option grant date fair values are calculated based on the Black-Scholes option pricing model as of date of grant. The valuation assumptions used to calculate the fair values of the stock options held by the PEO and NEOs as a group that vested during or were outstandin… | |
| 2024-04-25 DEF 14A | Peer Group Issuers Footnote | 2023-01-01..2023-12-31 | (6) Represents the weighted peer group TSR, weighted according to the respective companies’ stock market capitalization at the beginning of each period for which a return is indicated. The peer group used for this purpose is the following published industry index: Nasdaq Biotechnology Index. | |
| 2024-04-25 DEF 14A | Compensation Actually Paid Vs Net Income | 2023-01-01..2023-12-31 | Analysis of Information Presented in Pay-Versus-Performance Table As described in more detail in “ Executive Compensation – Compensation Discussion and Analysis ,” our executive compensation program reflects a variable “pay-for-performance” philosophy. While over the years we have used several diffe… | |
| 2024-04-25 DEF 14A | Compensation Actually Paid Vs Company Selected Measure | 2023-01-01..2023-12-31 | Analysis of Information Presented in Pay-Versus-Performance Table As described in more detail in “ Executive Compensation – Compensation Discussion and Analysis ,” our executive compensation program reflects a variable “pay-for-performance” philosophy. While over the years we have used several diffe… | |
| 2024-04-25 DEF 14A | Compensation Actually Paid Vs Total Shareholder Return | 2023-01-01..2023-12-31 | Analysis of Information Presented in Pay-Versus-Performance Table As described in more detail in “ Executive Compensation – Compensation Discussion and Analysis ,” our executive compensation program reflects a variable “pay-for-performance” philosophy. While over the years we have used several diffe… | |
| 2024-04-25 DEF 14A | Total Shareholder Return Vs Peer Group | 2023-01-01..2023-12-31 | Analysis of Information Presented in Pay-Versus-Performance Table As described in more detail in “ Executive Compensation – Compensation Discussion and Analysis ,” our executive compensation program reflects a variable “pay-for-performance” philosophy. While over the years we have used several diffe… | |
| 2024-04-25 DEF 14A | Tabular List Table | 2023-01-01..2023-12-31 | Table of Performance Measures: As discussed in greater detail in the “Executive Compensation – Compensation Discussion and Analysis,” the actual amount of bonus compensation that is earned by our NEOs is a discretionary determination made by the Board of Directors based on the recommendation of the … | |
| 2024-04-25 DEF 14A | Additional402v Disclosure | 2023-01-01..2023-12-31 | Pay Versus Performance: Conclusions The Compensation Committee believes in “pay for performance” and has structured our compensation program to reward our executive officers when we are delivering strong results. As discussed in more detail in “2023 Business and Financial Highlights” the progress ac… |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |